Warning
STUDY SUMMARY

STUDY SUMMARY: Beat AML Baseline Clinical - Phosphoproteome

211
Cases
211
Aliquots
SUMMARY
PDC Study IdentifierPDC000478Analytical FractionPhosphoproteome
Study ID6a52970d-b69d-43ab-b88b-1c21eaacd41cDisease TypesAcute Myeloid Leukemia;Myelodysplastic Syndromes;Other;Other Leukemias
Study NameBeat AML Baseline Clinical - PhosphoproteomeProject IDProteogenomic Translational Research Centers (PTRC)
Experiment TypeTMT11

Acute myeloid leukemia is a poor prognosis cancer commonly stratified by genetic aberrations, but these mutations are often heterogeneous and don’t always predict therapeutic response. Here we combine transcriptomic, proteomic, and phosphoproteomic datasets with ex vivo drug sensitivity data to help understand the underlying pathophysiology of AML beyond mutations. We measured the proteome and phosphoproteome of 210 patients and combined them with transcriptomic measurements to identify four proteogenomic subtypes that complemented existing genetic subtypes. We used these subtypes to classify additional samples and map them to a ‘landscape’ that identified specific drug response patterns that predicted efficacious drug combinations. We then built a drug response prediction model to identify drugs that target distinct subtypes and validated our findings on cell lines representing various stages of quizartinib resistance. Our results show how multi-omics data together with drug sensitivity data can inform therapy stratification and drug combinations in AML.

Common Data Analysis Pipeline (PDC Harmonization) data
Data CategoryFiles (n=1016)
Raw Mass Spectra (Proprietary)252
Processed Mass Spectra (Open Standard)252
Peptide Spectral Matches (Open Standard)252
Peptide Spectral Matches (Text)252
Protein Assembly (Text)6
Quality Metrics (Text)1
Quality Metrics (Web)1
Supplementary data
Data CategoryFiles (n=0)
Explore protein quantitation from PDC Common
Data Analysis pipeline (CDAP) through heatmaps
PUBLICATIONS
No publications